“A category 1 designation from the NCCN is not just a footnote change — it’s a signal flare,” said Dr. Aaron Gerds, MD, a hematologist, clinical investigator in MPNs, and Chair of the NCCN Myeloproliferative Neoplasms Panel. “It tells clinicians, patients, and payers that the data have matured to the point where this is no… Read More »NCCN updates guidance on interferon in essential thrombocythemia

In the clinic with a young MPN patient  A young adult sits across from Dr. Linda Resar, hands clasped, voice unsteady. The diagnosis is a mouthful — a myeloproliferative neoplasm (MPN) — and feels impossible. As Resar explains, “They go to the internet and they say, ‘Wow, I have cancer! I’m so young! This has to be devastating.’”   She slows the… Read More »Research spotlight: Dr. Linda Resar

Inside the Orlando Convention Center, a room as vast as an airline hangar was bathed in green light from numerous two-story-high screens. Thousands of hematology researchers filled the space, waiting for a marquee lecture.  This was the Ernest Beutler Lecture and Prize session at the American Society of Hematology’s (ASH) 2025 annual meeting — one of hematology’s… Read More »The power of persistence: MPN researchers honored with Ernest Beutler Prize at ASH 2025